Shots:

• The P-III trial evaluating Keytruda + CT vs CT alone in 816 patients with stage III-IV or recurrent EC whose cancer was either pMMR or dMMR
• The results showed an improvement in PFS regardless of mismatch repair status. In the pMMR & dMMR cohort of 591 & 225 evaluable patients, 46% & 70% reduction in risk of disease progression or death after a median follow-up of 7.9 & 12mos., m-PFS (13.1 vs 8.7mos. & not reached vs 7.6mos.), respectively
• The safety profile was consistent with prior reported studies with no new safety signals. In both cohorts, grade 3-5 AEs (55.1% vs 45.3% & 63.3% vs 47.2%) & no Keytruda-related AEs led to death. The results are being presented at SGO 2023; published in the NEJM & discussed with regulatory authorities globally
   

  Ref: keytruda  | Image: keytruda